REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
Regenxbio Inc RGNX
News
REGENXBIO to Participate in Upcoming Investor Conferences
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
REGENXBIO Announces Proposed Public Offering of Common Stock
Regenxbio Shares Rise on $100 Million Milestone Payment After First Patient Dosed in Eye-Disease Trial
Regenxbio Shares Up on WSJ Report of FDA U-Turn on Company's Gene Therapy
This biotech's stock soared after a 'polarizing' FDA official is stepping down
Regenxbio Shares Fall After FDA Declines Approval of Hunter Syndrome Treatment
FDA Declines to Approve Regenxbio's Hunter Syndrome Treatment
Regenxbio Shares Plunge on FDA Pausing Two Drug Development Programs
United States